DK1086082T3 - Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonister - Google Patents

Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonister

Info

Publication number
DK1086082T3
DK1086082T3 DK99926152T DK99926152T DK1086082T3 DK 1086082 T3 DK1086082 T3 DK 1086082T3 DK 99926152 T DK99926152 T DK 99926152T DK 99926152 T DK99926152 T DK 99926152T DK 1086082 T3 DK1086082 T3 DK 1086082T3
Authority
DK
Denmark
Prior art keywords
methyl
amine
penten
pyridyl
aryl
Prior art date
Application number
DK99926152T
Other languages
Danish (da)
English (en)
Inventor
William Scott Caldwell
Gary Maurice Dull
Balwinder Singh Bhatti
Peter Anthony Crooks
Srishailkumar B Hadimani
Haeil Park
Jared Miller Wagner
Patrick Michael Lippiello
Merouane Bencherif
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/098,133 external-priority patent/US6232316B1/en
Application filed by Targacept Inc filed Critical Targacept Inc
Application granted granted Critical
Publication of DK1086082T3 publication Critical patent/DK1086082T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Cosmetics (AREA)
DK99926152T 1998-06-16 1999-06-03 Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonister DK1086082T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9828598A 1998-06-16 1998-06-16
US09/098,133 US6232316B1 (en) 1998-06-16 1998-06-16 Methods for treatment of CNS disorders
EP99926152A EP1086082B9 (en) 1998-06-16 1999-06-03 Arylsubstituted olefinic amines and their use as cholinergic receptors agonists

Publications (1)

Publication Number Publication Date
DK1086082T3 true DK1086082T3 (da) 2004-11-22

Family

ID=26794206

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99926152T DK1086082T3 (da) 1998-06-16 1999-06-03 Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonister

Country Status (12)

Country Link
EP (1) EP1086082B9 (enExample)
JP (4) JP4240815B2 (enExample)
KR (1) KR100593433B1 (enExample)
AT (1) ATE273956T1 (enExample)
AU (1) AU4230799A (enExample)
BR (1) BR9911325A (enExample)
CA (3) CA2709735A1 (enExample)
DE (1) DE69919537T2 (enExample)
DK (1) DK1086082T3 (enExample)
ES (1) ES2228054T3 (enExample)
PT (1) PT1086082E (enExample)
WO (1) WO1999065876A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
JP4240815B2 (ja) * 1998-06-16 2009-03-18 ターガセプト,インコーポレイテッド アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用
EP1185514A1 (en) * 1999-06-07 2002-03-13 Targacept, Inc. Pharmaceutical compositions and methods for use
WO2001016107A1 (en) * 1999-08-31 2001-03-08 Targacept, Inc. Arylalkyloxyalkylamines and arylalkylthioalkylamines, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
AU2001257449A1 (en) * 2000-05-01 2001-11-12 Targacept, Inc. Imaging of nicotinic acetylcholine receptor subtypes
US6432954B1 (en) * 2000-07-14 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
PL374384A1 (en) 2001-12-14 2005-10-17 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
PT1678172E (pt) 2003-10-15 2010-03-03 Targacept Inc Composições farmacêuticas e métodos para alívio da dor e tratamento de perturbações do sistema nervoso central
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型
EP2133337A1 (en) 2006-05-09 2009-12-16 AstraZeneca AB Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine
EP2255848A3 (en) 2006-09-04 2011-04-06 NeuroSearch AS Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
KR20100052490A (ko) * 2007-07-31 2010-05-19 타가셉트 인코포레이티드 (2s)-(4e)-n-메틸-5-(3-(5-이소프로폭시피리딘)일)-4-펜텐-2-아민의 경피투여
US8703775B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
ES2455197T3 (es) 2007-12-07 2014-04-14 Abbvie Deutschland Gmbh & Co Kg Derivados de oxindol 5,6-disustituidos y el uso de los mismos para la preparación de un medicamento para el tratamiento de enfermedades dependientes de vasopresina
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
NZ586651A (en) 2007-12-07 2012-06-29 Abbott Gmbh & Co Kg 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US9463190B2 (en) 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
AU2011256866B2 (en) * 2010-05-20 2014-05-22 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines
WO2013184732A1 (en) * 2012-06-06 2013-12-12 Targacept, Inc. Crystalline (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]4-penten-2-amine 1,5-naphthalenedisulfonate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242935A (en) * 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5597716A (en) * 1993-11-18 1997-01-28 Mitsubishi Rayon Co., Ltd. Process for producing D-lactic acid and L-lactamide
EP0801527B1 (en) * 1995-01-06 2006-07-26 Targacept, Inc. Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5616707A (en) * 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
WO1996036637A1 (en) * 1995-05-17 1996-11-21 R.J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
ES2318856T4 (es) * 1996-04-23 2010-03-03 Targacept, Inc. Composiciones farmaceuticas para la prevencion y el tratamiento de trastornos del sistema nervioso central.
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
CA2281564A1 (en) * 1997-02-21 1998-08-27 R.J. Reynolds Tobacco Company Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
JP4240815B2 (ja) * 1998-06-16 2009-03-18 ターガセプト,インコーポレイテッド アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用

Also Published As

Publication number Publication date
JP4896923B2 (ja) 2012-03-14
JP2010229149A (ja) 2010-10-14
JP2002518373A (ja) 2002-06-25
DE69919537T2 (de) 2005-09-08
KR20010083052A (ko) 2001-08-31
EP1086082A1 (en) 2001-03-28
PT1086082E (pt) 2005-01-31
CA2709735A1 (en) 1999-12-23
CA2334923C (en) 2009-09-29
AU4230799A (en) 2000-01-05
ATE273956T1 (de) 2004-09-15
JP4972608B2 (ja) 2012-07-11
JP2008260774A (ja) 2008-10-30
JP2008255122A (ja) 2008-10-23
CA2677519A1 (en) 1999-12-23
EP1086082B1 (en) 2004-08-18
BR9911325A (pt) 2001-04-03
WO1999065876A1 (en) 1999-12-23
EP1086082B9 (en) 2005-03-02
CA2334923A1 (en) 1999-12-23
DE69919537D1 (de) 2004-09-23
KR100593433B1 (ko) 2006-06-28
ES2228054T3 (es) 2005-04-01
JP4240815B2 (ja) 2009-03-18

Similar Documents

Publication Publication Date Title
DK1086082T3 (da) Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonister
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
BR9810342A (pt) Novos compostos imidazola substituìdos
DE60122175D1 (de) Chemokin rezeptor bindenden heterozyklischen verbindungen
TR200102029T2 (tr) 1-Heterosiklil ikameli diarilaminler.
DK1311269T3 (da) Fremgangsmåde til anvendelse af diketopiperaziner og sammensætning, som indeholder dem
DK1114031T3 (da) 4-carboxyamino-2-substituerede 1,2,3,4.tetrahydroquinoliner som CETP-inhibitorer
NO20031619D0 (no) Substituerte indoler, farmasöytiske blandinger inneholdende slike indoler og deres anvendelse som PPAR-gamma-bindende midler
TR200300322T2 (tr) Kemokin alıcısını bağlayan heterosiklik bileşikler
DK1114032T3 (da) 4-aminosubstituerede-2-substituerede-1,2,3,4-tetrahydroquinoliner som CETB-inhibitorer
ID30460A (id) Inhibitor-inhibitor protein siklik tirosin kinase
TR200000782T2 (tr) Resorsinol türevleri.
PT935465E (pt) Compostos novos de imidazole substituido
ATE266399T1 (de) Neue substituierte triazolverbindungen
UY26451A1 (es) Procedimiento para la obtención de 1,2,3,4- tetrahidroquinolinas 4-carboxiamino-2-sustituidas
TR199800077T1 (xx) Kontroll� ��z�len paroksetin terkipleri.
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
TR200103276T2 (tr) Yeterince yağsız siklosporin kompozisyonları
NO20003451D0 (no) 2,3-substituerte indolforbindelser som cox-2 inhibitorer
DK1017684T3 (da) Kontrastmiddel til afbildning af infarkter og nekroser
TR200001452T2 (tr) Bifenilamidin türevleri.
BR0112600A (pt) Compostos calcilìticos
NO307462B1 (no) Imidazopyridin-azolidinoner
BR9912307A (pt) Inibidores fkbp
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer